Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide 25 mg versus 5 mg maintenance after autologous stem cell transplantation in multiple myeloma
2007-003945-33Phase 3Completed
- Sponsor
- GMIHO
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by GMIHO. Primary endpoint: Event-free survival. Started Jul 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-003945-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003945-33.